Comparative Pharmacology
Head-to-head clinical analysis: DORIBAX versus PRIMAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORIBAX versus PRIMAXIN.
DORIBAX vs PRIMAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doripenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic bacteria.
Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death. Cilastatin prevents renal metabolism of imipenem by inhibiting dehydropeptidase I.
1 g IV every 8 hours over 1 hour for complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), and hospital-acquired pneumonia (including ventilator-associated pneumonia).
1 g (imipenem 500 mg + cilastatin 500 mg) IV every 6 hours for adults with normal renal function. Maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life approximately 1 hour in healthy adults; prolonged to ~4 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 1 hour. In patients with impaired renal function, half-life extends up to 4-6 hours in moderate impairment and >10 hours in severe impairment.
Renal: approximately 70-75% unchanged in urine; biliary/fecal: minimal (less than 20% total, primarily as metabolite).
Renal (approximately 70% as unchanged drug via glomerular filtration and tubular secretion) and 20-30% biliary/fecal.
Category C
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic